FindTrial
Sign In

PHASE III RANDOMIZATION OF DOXORUBYCIN AND CYCLOPHOSPHAMID (AC) FOLLOWED BY WEEKLY PACLITAXEL WITH OR WITHOUT TRASTUZUMAB AS AN ADJUVANT TREATMENT FOR WOMEN WITH BREAST CANCER WITH POSITIVE GANGLES ON EXPRESSING HER-2 POSITIVE

PHASE III RANDOMIZATION OF DOXORUBYCIN AND CYCLOPHOSPHAMID (AC) FOLLOWED BY WEEKLY PACLITAXEL WITH OR WITHOUT TRASTUZUMAB AS AN ADJUVANT TREATMENT FOR WOMEN WITH BREAST CANCER WITH POSITIVE GANGLES ON EXPRESSING HER-2 POSITIVE

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REPEC
Registry ID
PER-073-03
Enrollment
13
Registered
2004-01-22
Start date
Unknown
Completion date
Unknown
Last updated
2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

TRANSUMAB+ DOXORUBYCIN + CYCLOPHOSFAMIDE + PACLITAXEL Type of group
1DOXORUBYCIN AND CYCLOPHOSFAMID FOLLOWED BY PACLITAXEL WEEKLY AS AN ADJUVANT TREATMENT FOR WOMEN WITH BREAST CANCER WITH POSITIVE GANGLES ON EXPRESSING HER-2 POSITIVE Group name:Paclitaxel Type of group
Paclitaxel 80 mg/m IV Cada semanas x 12 luego observacion.

Sponsors

EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG),
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Operable, histologically confirmed adenocarcinoma of the female breast and positive lymph nodes. The positivity of the ganglion could be determined by axillary node dissection or positive sentinel node discovery by H & E. One or more positive lymph nodes whose tumors are T1-3, pN1-2, MO are eligible.

Exclusion criteria

Exclusion criteria: Minors. Pregnant The CN2 disease is not eligible.

Design outcomes

Primary

MeasureTime frame
Outcome name:not contemplated Measure:not contemplated Timepoints:not contemplated—

Secondary

MeasureTime frame
Outcome name:not contemplated Measure:not contemplated Timepoints:not contemplated—

Countries

Peru, United States

Outcome results

None listed

Source: REPEC (via WHO ICTRP)